MiMedx Group, Inc (NASDAQ:MDXG) Receives $9.50 Consensus Price Target from Brokerages

Shares of MiMedx Group, Inc (NASDAQ:MDXG) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $9.60.

MDXG has been the topic of a number of recent research reports. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Citigroup began coverage on MiMedx Group in a report on Monday. They issued a “market outperform” rating on the stock. Cantor Fitzgerald reduced their price target on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. Finally, Mizuho dropped their price target on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 17th.

Trending Headlines about MiMedx Group

Here are the key news stories impacting MiMedx Group this week:

• Positive Sentiment: Q4 beat — MiMedx posted EPS of $0.14 vs. the $0.09 consensus and reported revenue of ~$118.1M, well above estimates; margins and ROE remained healthy, supporting the operational story. MiMedx Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Record results & buyback — The company announced record Q4 and FY2025 operating results and authorized a $100M share repurchase program, which can support the stock over time. MIMEDX Announces Record Fourth Quarter and Full-Year 2025 Results
• Neutral Sentiment: Full disclosure & commentary — Management hosted an earnings call (transcripts available) providing color on surgical growth initiatives and how the company plans to manage reimbursement shifts; useful for modeling but not an immediate price driver. MiMedx Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analyst coverage update — Citizens JMP began coverage, which may influence liquidity and analyst attention but has mixed near-term impact. Citizens JMP Begins Coverage on MiMedx
• Negative Sentiment: Below-Cons. FY2026 revenue guide — Management guided revenue of $340M–$360M for 2026, below the consensus (~$375M), citing reimbursement changes and a shift toward surgical growth that may take time to scale; that guidance shortfall is the primary negative catalyst. MiMedx targets $340M–$360M 2026 revenue while navigating reimbursement changes
• Negative Sentiment: Reimbursement risk — Management highlighted evolving reimbursement dynamics that could pressure near-term top-line growth and create execution risk as sales mix shifts toward surgical channels. MiMedx Q4 2025 Earnings Call Transcript (seekingalpha)

MiMedx Group Stock Performance

Shares of MDXG stock opened at $5.28 on Monday. The company has a market capitalization of $781.97 million, a P/E ratio of 19.56 and a beta of 1.59. MiMedx Group has a fifty-two week low of $4.89 and a fifty-two week high of $8.46. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41. The stock has a 50 day moving average price of $5.78 and a two-hundred day moving average price of $6.60.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. The company had revenue of $118.10 million for the quarter, compared to analysts’ expectations of $106.78 million. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%. Analysts expect that MiMedx Group will post 0.3 earnings per share for the current year.

Hedge Funds Weigh In On MiMedx Group

A number of hedge funds have recently added to or reduced their stakes in MDXG. CWM LLC boosted its stake in MiMedx Group by 63.8% during the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after purchasing an additional 1,892 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of MiMedx Group by 1,808.4% during the second quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock valued at $46,000 after purchasing an additional 7,107 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of MiMedx Group during the fourth quarter valued at $48,000. State of Alaska Department of Revenue bought a new stake in MiMedx Group in the 3rd quarter worth about $54,000. Finally, Headlands Technologies LLC purchased a new position in MiMedx Group in the 2nd quarter worth about $72,000. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.